Shire resubmits NDA for Lifitegrast to US FDA

25 January 2016

Ireland-headquartered Shire (LSE: SHP) said today it has resubmitted the New Drug Application to the US Food and Drug Administration for its investigational candidate, lifitegrast, for the treatment of signs and symptoms of dry eye disease in adults.

Shire resubmitted the NDA in response to the Complete Response Letter (CRL) the company received from the FDA last fall (The Pharma Letter October 17, 2015).

Assuming approval, it is estimated the drug could generate $1.5 billion in sales for the company, although analysts at UBS have suggested that peak sales of $2 billion are possible, noting that “consensus (risk-adjusted) sales of $630 million in 2020 seem substantially too low.”

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK